GPR146抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: A172 cell lysate, Primary antibody: P06596(GPR146 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06596(GPR146 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06596(GPR146 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The G protein-coupled receptor 146 (GPR146), also known as PGR8. is an orphan receptor belonging to the class A GPCR family. Its endogenous ligand and precise physiological roles remain poorly characterized, though emerging evidence suggests involvement in metabolic regulation, particularly lipid and glucose homeostasis. GPR146 is expressed in various tissues, including the liver, pancreas, and cardiovascular system, and has been linked to conditions such as atherosclerosis, diabetes, and hepatic steatosis in preclinical studies. Due to the lack of definitive functional data, research tools like antibodies are critical for elucidating its expression patterns and mechanisms.

GPR146 antibodies are typically developed using immunogens derived from conserved regions of its extracellular or intracellular domains, such as synthetic peptides or recombinant protein fragments. These antibodies enable detection of endogenous GPR146 via techniques like Western blotting, immunohistochemistry, and flow cytometry. Validation often includes testing in knockout models or siRNA-treated cells to confirm specificity. Commercially available antibodies vary in host species (e.g., rabbit, mouse) and clonality (monoclonal/polyclonal), with applications spanning basic research to biomarker studies. Challenges include low endogenous expression levels in certain tissues and potential cross-reactivity with homologous GPCRs. Ongoing studies using these antibodies aim to clarify GPR146's signaling pathways and its potential as a therapeutic target for metabolic disorders.